Italy's Pharma Firms Relaunching R&D

24 November 1997

Farmindustria, Italy's pharmaceutical companies' federation, ispromoting a platform aimed at relaunching research and development in this sector.

According to Farmindustria chairman Federico Nazzari, negotiations are ongoing with the government, and the federation proposes to make research-based drugmakers and groups the link between public and private research efforts, and believes the Scientific Research Ministry should put forth directives to this end. The federation adds that a special committee, with both private and state financing, should single out strategic areas and methodologies. It would also revise current researchers' status.

As to incentives and state financing, Farmindustria asks that criteria for eligibility for small- and medium-sized firms be revised to better reflect current conditions. The federation proposes that tax credits and discounts on social security payments be introduced as incentives, and it also asks that procedures on access to public funds be simplified.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight